Update: Oxford University/AstraZeneca COVID-19 vaccine regulatory approval

Dear Colleague,

We have updated our information below for COVID-19 Vaccine AstraZeneca developed by Oxford University/AstraZeneca:

Information for healthcare professionals – describes the medicinal product’s properties and the conditions attached to its use. It also explains how to use and prescribe a medicine.
Information for UK recipients – provides information for patients on using the medicine safely.
Public Assessment Report – is a scientific report written by us. It explains how the product was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use the vaccine.
Conditions of authorisation for COVID-19 Vaccine AstraZeneca

New information includes updated efficacy and adverse drug reaction data.

Please see the Decision page on our website which has more details about COVID-19 Vaccine AstraZeneca.

If you have any further questions about the MHRA’s process for reviewing and approving this vaccine, please email info@mhra.gov.uk.

Patient, Public and Stakeholder Engagement team
Communications division

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone: 0203 080 6000
Email: engagement@mhra.gov.uk
gov.uk/mhra

Read our guidance on coronavirus (COVID-19)

If you would like to share this with a friend or colleague, hit the Forward button or send them this link to view the email in a browser.

Unsubscribe or change your email address at any time on your subscriber preferences page.

If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

All other enquiries can be directed to email.support@mhra.gov.uk.

This is an automatically generated email. Please do not reply directly to this notification.
This service is provided to you at no charge by the Medicines and Healthcare products Regulatory Agency.